CABRELLIS PHARMACEUTICALS

cabrellis-pharmaceuticals-logo

Cabrellis Pharmaceuticals Corporation, a specialty pharmaceutical company developing therapies for the treatment of cancer. Cabrellis plans to initiate three separate clinical trials in small cell lung cancer (SCLC) in 2006. The first trial, designed to assess the safety and efficacy of Calsed(TM) in reference to topotecan in the second-line treatment of patients with SCLC who previously responded to platinum-based chemotherapy, is currently underway at multiple clinical trial sites in the United States.

#SimilarOrganizations #Financial #More

CABRELLIS PHARMACEUTICALS

Industry:
Health Care Health Diagnostics Pharmaceutical Therapeutics

Founded:
2006-01-01

Address:
San Diego, California, United States

Country:
United States

Total Employee:
11+

Status:
Active

Contact:
(858)404-1777

Total Funding:
27.5 M USD


Similar Organizations

conforma-therapeutics-logo

Conforma Therapeutics

Conforma Therapeutics Corporation designs and develops drugs for the treatment of cancer.

novita-pharmaceuticals-logo

Novita Pharmaceuticals

Novita Pharmaceuticals is a developer of therapeutic drugs for the treatment of cancer.

therinject-logo

Therinject

Therinject is a pharmaceutical company focused on developing therapeutics for the treatment of cancer.

Investors List

novo-a-s_image

Novo Holdings

Novo Holdings investment in Series A - Cabrellis Pharmaceuticals

lilly-ventures_image

Lilly Ventures

Lilly Ventures investment in Series A - Cabrellis Pharmaceuticals

rivervest_image

RiverVest

RiverVest investment in Series A - Cabrellis Pharmaceuticals

domain-associates_image

Domain Associates

Domain Associates investment in Series A - Cabrellis Pharmaceuticals

rbc-venture-partners_image

RBC Venture Partners

RBC Venture Partners investment in Series A - Cabrellis Pharmaceuticals

forward-ventures_image

Forward Ventures

Forward Ventures investment in Series A - Cabrellis Pharmaceuticals

sr-one_image

SR One

SR One investment in Series A - Cabrellis Pharmaceuticals

proquest-investments_image

ProQuest Investments

ProQuest Investments investment in Series A - Cabrellis Pharmaceuticals

More informations about "Cabrellis Pharmaceuticals"

Cabrellis Pharmaceuticals - Funding, Financials, Valuation

Cabrellis Pharmaceuticals Corporation develops therapies for the treatment of cancer. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. Pricing. ...See details»

Pharmion - Funding, Financials, Valuation & Investors - Crunchbase

Pharmion has acquired Cabrellis Pharmaceuticals on Nov 15, 2006. They acquired Cabrellis Pharmaceuticals for $59M. Which types of acquisition does this organization make most โ€ฆSee details»

Press Release: Pharmion Acquires Cabrellis Pharmaceuticals

Nov 16, 2006 Dainippon Sumitomo Pharmaceuticals, the original developer of amrubicin, licensed the Japanese marketing rights to Nippon Kayaku in January 2005, and the North โ€ฆSee details»

Pharmion Acquires Cabrellis Pharmaceuticals

Nov 16, 2006 Dainippon Sumitomo Pharmaceuticals, the original developer of amrubicin, licensed the Japanese marketing rights to Nippon Kayaku in January 2005, and the North โ€ฆSee details»

Cabrellis Pharmaceuticals - PitchBook

How much funding has Cabrellis Pharmaceuticals raised over time? Cabrellis Pharmaceuticals has raised $27.5M. Who are Cabrellis Pharmaceuticalsโ€™s investors? Domain Associates, โ€ฆSee details»

Pharmion Acquires Cabrellis Pharmaceuticals, Gains Rights To โ€ฆ

Dec 4, 2006 Pharmion Corporation announced that it has acquired Cabrellis Pharmaceuticals, a clinical-stage private oncology company dedicated to the development of amrubicin, a third โ€ฆSee details»

Cabrellis Pharmaceuticals Corporation Company Profile | Summit, โ€ฆ

Find company research, competitor information, contact details & financial data for Cabrellis Pharmaceuticals Corporation of Summit, NJ. Get the latest business insights from Dun & โ€ฆSee details»

Cabrellis Pharmaceuticals Corp - Company Profile and News

Company profile page for Cabrellis Pharmaceuticals Corp including stock price, company news, executives, board members, and contact informationSee details»

Pharmion - M&A Summary, Ownership, and Business Overview

Nov 18, 2007 Pharmion has acquired 1 company of its own. Pharmionโ€™s largest acquisition to date was in 2006, when it acquired Cabrellis Pharmaceuticals for $59M. Pharmion has โ€ฆSee details»

Pharmion Acquires Cabrellis Pharmaceuticals - socaltech.com

Nov 16, 2006 Pharmion Acquires Cabrellis Pharmaceuticals. Boulder, Colorado-based Pharmion said late yesterday that it has acquired San Diego, California-based Cabrellis โ€ฆSee details»

Pharmion Acquires Cabrellis Pharmaceuticals - techrockies.com

Nov 16, 2006 Pharmion Acquires Cabrellis Pharmaceuticals. Boulder, Colorado-based Pharmion said late yesterday that it has acquired San Diego, California-based Cabrellis โ€ฆSee details»

Cabrellis Pharmaceuticals acquired by Pharmion - Crunchbase

Nov 15, 2006 Pharmion acquires Cabrellis Pharmaceuticals on 2006-11-15 for $59000000. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. ...See details»

Pharmion Acquires Cabrellis: $59M For Lung Cancer Drug

Nov 17, 2006 The amrubicin license became the main focus of specialty pharma firm Cabrellis, carved out of the Biogen arrangement. (See BioWorld Today, May 4, 2006.) "I was selling the โ€ฆSee details»

Pharmion Purchases Cabrellis, US Developer of Amrubicin

Dec 1, 2006 Pharmion Corporation has acquired Cabrellis Pharmaceuticals and gained US and European rights to amrubicin, a third-generation synthetic anthracycline currently in phase II โ€ฆSee details»

Pharmion nets cancer therapy in Cabrellis buyout

Nov 15, 2006 Pharmion has acquired a mid-stage lung cancer therapy--amrubicin--in its deal to buy Cabrellis Pharmaceuticals for $59 million up front. Cabrellis shareholders will also get โ€ฆSee details»

Cabrellis Pharmaceuticals - Crunchbase

Cabrellis Pharmaceuticals Corporation develops therapies for the treatment of cancer.See details»

Thomas Estok โ€“ Dracen Pharmaceutical

Mr. Estok brings 30+ years of experience in development and commercialization of pharmaceuticals to Dracen. Previously, he was the founding President/CEO of Tragara โ€ฆSee details»

Chris LeMasters - MBrace Therapeutics

He has co-founded and served as a management team member for several biotherapeutics companies, including Cabrellis Pharmaceuticals (acquired by Pharmion), Conforma โ€ฆSee details»

Cabrellis Pharmaceuticals - Tech Stack, Apps, Patents & Trademarks

Cabrellis Pharmaceuticals Corporation develops therapies for the treatment of cancer.See details»

linkstock.net © 2022. All rights reserved